Certara to Participate in Upcoming Investor Conferences
Certara (Nasdaq: CERT), a global leader in model-informed drug development, has announced its participation in two upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara (Nasdaq: CERT), a global leader in model-informed drug development, has announced its participation in two upcoming investor conferences in September 2025.
Management will present at the Baird Global Healthcare Conference on Tuesday, September 9 at 10:15 a.m. ET, followed by the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10 at 12:20 p.m. ET. Both presentations will be available via webcast on Certara's investor relations website with replay access for 90 days.
Details
News Market Reaction – CERT
On Sep 3, the first trading day after this news, CERT closed 1.50% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
- Baird Global Healthcare Conference
Date and Time: Tuesday, September 9 at 10:15 a.m. ET
- Morgan Stanley 23rd Annual Global Healthcare Conference
Date and Time: Wednesday, September 10 at 12:20 p.m. ET
Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.